Lunai Bioworks Inc. 8-K

What Happened Lunai Bioworks Inc. announced that on February 6, 2026 it received a letter from the Nasdaq Listing Qualifications Staff notifying the company of a determination to delist its securities from Nasdaq. The company timely requested a hearing, and on February 17, 2026 Nasdaq notified Lunai that the Nasdaq Hearings Panel granted the hearing. The hearing is scheduled for March 26, 2026. As a result of the hearing request, the delisting action is stayed pending the Panel’s final written decision.

Key Details

• Nasdaq Listing Qualifications Staff issued the delisting determination letter received by the company on February 6, 2026.
• Lunai requested a hearing; the Nasdaq Hearings Panel granted the hearing on February 17, 2026.
• Hearing date: March 26, 2026.
• The delisting action is stayed while the Panel reviews the matter; the Panel’s final decision is not guaranteed.

Why It Matters A delisting determination and pending hearing are material events for shareholders because removal from Nasdaq would affect where and how the company’s shares trade, potentially reducing liquidity and investor access. The stay preserves the company’s Nasdaq listing for now, but there is no assurance the Panel will allow continued listing or that Lunai will meet Nasdaq’s listing requirements. Investors should monitor the outcome of the March 26, 2026 hearing and subsequent filings for updates.